Drug Name: Imjudo
Active Ingredient: tremelimumab
Indications: To treat unresectable hepatocellular carcinoma
Approval Date: 10/21/2022
Company: AstraZeneca Pharmaceuticals LP
Learn more: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761289s001lbl.pdf